| Prev Close | 6.77 |
| Day Low/High | 6.53 / 6.84 |
| 52 Wk Low/High | 4.00 / 11.72 |
| Avg Volume | 1.17M |
| Exchange | NASDAQ |
| Shares Outstanding | 70.23M |
| Market Cap | 475.42M |
| EPS | 0.10 |
| P/E Ratio | 67.70 |
| Div & Yield | N.A. (N.A) |
Latest News
Short Interest Expands By 13.2% For PGNX
The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 928,274 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 7,977,161, an increase of 13.17% since 03/31/2017.
PGNX Crosses Below Key Moving Average Level
In trading on Friday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.82, changing hands as low as $7.67 per share.
Short Interest Drops 23% For PGNX
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,093,733 share decrease in total short interest for Progenics Pharmaceuticals, Inc. , to 7,048,887, a decrease of 22.90% since 03/15/2017.
What Poker Taught Me About Investing
I've learned that emotions have little use at a poker table; they don't in the stock market, either.
What Poker Taught Me About Investing
I've learned that emotions have little use at a poker table; they don't in the stock market, either.
First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the November 17th expiration.
4 Small-Cap Biotech Stars
I'm still enthusiastic about the sector, but it is critical to also be prudent.
4 Small-Cap Biotech Stars
I'm still enthusiastic about the sector, but it is critical to also be prudent.
Biotech Premarket Movers: Progenics, Alexion, BioCryst
Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.
First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the March 17th expiration.
Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options
Investors considering a purchase of Progenics Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $8.79/share, might benefit from considering selling puts among the alternative strategies at their disposal.
My Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher this year.
Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher next year.
Progenics Pharmaceuticals Announces First Patient Dosed In Phase 2/3 Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL™
Study to Enroll 300 Patients in U.S. and Canada
'Yuge' Sector Rotation Will Continue
What's in, what's out and who should thrive in the new political landscape.
Biotech Hits an Inflection Point
The worst appears to be over for this sector; we could see big growth ahead.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHP, ARCX, ATNI, HTGC, MGM, PGNX, PGRE, SGMS, SYF, WABC Downgrades: ABDC, ARCC, ARII, BOJA, CTLT, FSM, GEL, H, KMPR, LBTYA, LBTYB, LBTYK, TSCO Initiations: PEN, PSTG Read on to get TheStreet Quant Ratings' detailed report:
